Lantus Global Regulatory Status: FDA Approval, Label, and Post-Market Safety

When Was Lantus FDA Approved?

The FDA approved Lantus on April 20, 2000, making it the first long-acting insulin analog cleared for U.S. Marketing. The approval was issued under NDA 021081 to Aventis Pharmaceuticals, which was later acquired by Sanofi. The original indication covered adults with type 1 and type 2 diabetes; the pediatric indication for children aged 6 years and older with type 1 diabetes was added in a subsequent labeling supplement. The full approval package, including chemistry, manufacturing, and clinical review documents, is publicly available through Drugs@FDA.

The NDA 021081 Clinical Basis

The NDA rested on a series of Phase 3 randomized controlled trials comparing insulin glargine to NPH insulin. The core registration studies enrolled patients with type 1 and type 2 diabetes and demonstrated non-inferior glycemic control (HbA1c reduction) with a statistically significant reduction in nocturnal hypoglycemia rates 1. FDA reviewers noted that the once-daily, peakless pharmacokinetic profile was a clinically meaningful differentiation from NPH, supporting approval on both safety and efficacy grounds.

Pediatric Labeling Supplement

The pediatric supplement extended use to children aged 6 to 15 years with type 1 diabetes, based on a dedicated pharmacokinetic and efficacy study. The FDA Pediatric Research Equity Act (PREA) review concluded that the adult PK/PD data were sufficient to support the extension with a weight-based dosing note. Details of this supplement appear in the FDA labeling archive 2.

What Does the Lantus Label Say?

The current Prescribing Information for Lantus is a substantial document covering indications, dosing, contraindications, warnings, adverse reactions, drug interactions, and special populations. The full label is publicly available from FDA accessdata 2.

Indications and Approved Doses

Lantus is indicated to improve glycemic control in adults with type 2 diabetes mellitus and in adults and pediatric patients (aged 6 years and older) with type 1 diabetes mellitus. Dosing is individualized: in insulin-naive type 2 patients, the label recommends starting at 0.2 units/kg or 10 units once daily, then titrating every 3 to 4 days to a fasting glucose target 2. The label explicitly states that Lantus must not be diluted or mixed with any other insulin or solution, a safety requirement rooted in the acidic pH formulation (pH approximately 4) that maintains the drug's solubility before subcutaneous injection.

Warnings and Precautions

The label carries a prominent Boxed Warning for hypoglycemia, described as "the most common adverse reaction of insulin therapy, including Lantus." The warning notes that hypoglycemia can be life-threatening and that its frequency and severity depend on nutritional status, exercise, renal function, hepatic function, concurrent medications, and the dose administered 2.

Additional Warnings and Precautions sections address:

• Never share Lantus pens, cartridges, or syringes between patients (risk of blood-borne pathogen transmission).
• Changes in insulin regimen require close glucose monitoring.
• Hypokalemia: all insulins, including glargine, shift potassium intracellularly. Monitor patients on potassium-lowering agents or digitalis.
• Fluid retention and heart failure in patients also receiving thiazolidinediones.
• Allergic reactions, including anaphylaxis.

The label's Drug Interactions section identifies several clinically significant interactions. Antidiabetic agents, ACE inhibitors, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, and sulfonamide antibiotics can increase the blood-glucose-lowering effect and raise hypoglycemia risk 2. Corticosteroids, danazol, diuretics, glucagon, isoniazid, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics, and thyroid hormones may reduce efficacy and trigger hyperglycemia.

Contraindications

The label lists two contraindications: (1) hypersensitivity to insulin glargine or any of the product's excipients, and (2) during episodes of hypoglycemia. The FDA drug label guidance framework specifies that contraindications require "clear evidence of a serious hazard" that outweighs any potential benefit, and both listed contraindications meet that threshold 3.

Special Populations: Pregnancy and Lactation

Labeling under the Pregnancy and Lactation Risk Summary (implemented post-2014 FDA rule change) notes that available data from published studies and pharmacovigilance reports have not established a clear association between insulin glargine use and major birth defects, miscarriage, or adverse maternal/fetal outcomes. Because poorly controlled diabetes during pregnancy carries its own risks, the labeling supports continued use when clinically warranted 4. Animal reproductive studies using insulin glargine showed no teratogenicity at doses up to 8 times the human exposure. The Lactation subsection notes that endogenous insulin is present in human milk; no data exist on insulin glargine levels in milk, but oral bioavailability is negligible in nursing infants.

Lantus EMA and Global Regulatory Status

Outside the United States, insulin glargine received European Medicines Agency (EMA) approval in 2000 under a centralized procedure, allowing marketing authorization across all EU member states simultaneously. The EMA's European Public Assessment Report (EPAR) for Lantus documents the full scientific basis for approval and all subsequent labeling updates. The EMA product page and the WHO Model List of Essential Medicines both include insulin glargine as a recognized basal insulin agent 5.

Health Canada Approval

Health Canada authorized Lantus under Drug Identification Number (DIN) 02240294 in 2000. The Canadian Prescribing Summary aligns closely with the U.S. Label on dosing, contraindications, and warnings. Specific differences include Canadian labeling guidance on the use of insulin glargine during pregnancy, which references domestic pharmacovigilance data collected through the Canada Vigilance Program.

Access in Low- and Middle-Income Countries

Access to insulin glargine remains uneven globally. A 2021 Lancet Diabetes and Endocrinology analysis found that analog insulins, including glargine, were available in fewer than 50% of public-sector pharmacies surveyed across 13 low- and middle-income countries 6. The WHO's April 2023 prequalification program extended to insulin glargine biosimilars, aiming to improve affordable access. The WHO prequalification database lists currently qualified manufacturers.

Post-Market Safety Surveillance

The ORIGIN Trial

The most significant post-market safety commitment for Lantus was the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). ORIGIN enrolled 12,537 participants with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and a history of cardiovascular disease or cardiovascular risk factors. Participants were randomized to insulin glargine titrated to a fasting glucose of 95 mg/dL (5.3 mmol/L) or standard care. At a median follow-up of 6.2 years, ORIGIN found no significant difference in the rate of the primary composite cardiovascular endpoint (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death): hazard ratio 1.02 (95% CI 0.94 to 1.11) 7. This finding was central to FDA's conclusion that long-term glargine use did not carry excess cardiovascular risk.

The ORIGIN trial also addressed the pre-approval concern about insulin and cancer risk, a concern that arose from observational pharmacoepidemiologic data published in 2009 8. Over 6.2 years, ORIGIN found no statistically significant difference in incident cancer rates between the glargine arm and the standard-care arm (hazard ratio 1.00, 95% CI 0.88 to 1.13) 7.

FDA Sentinel System Monitoring

After ORIGIN, FDA continued pharmacovigilance through the Sentinel Distributed Database, a near-real-time active surveillance system that links claims and electronic health record data from more than 100 million U.S. Patients. A 2016 Sentinel analysis of basal insulins, including glargine, detemir, and degludec, examined severe hypoglycemia rates across product classes in routine clinical practice. The analysis confirmed that glargine's real-world severe hypoglycemia rate (defined as emergency department visit or hospitalization) was comparable to published trial rates, with no new safety signal identified 9.

The 2009 Cancer Signal and Resolution

In June 2009, four observational analyses published simultaneously in Diabetologia raised concern that insulin glargine might be associated with a higher cancer incidence than human insulin NPH, with one analysis reporting an adjusted hazard ratio of 1.31 (95% CI 1.20 to 1.42) for any cancer 8. FDA issued a safety communication acknowledging the signal but noting serious methodological limitations in all four studies, including immortal time bias and confounding by indication 9. The European Medicines Agency reached the same conclusion. Subsequent prospective data, including ORIGIN and a 2018 meta-analysis of randomized controlled trials (N=approximately 40,000 patient-years), found no statistically detectable excess cancer risk attributable to insulin glargine 10.

Post-Market Label Updates Related to Safety

Since the 2000 approval, the Lantus label has been updated through 67 supplements (as of the most recent publicly posted version). Key safety-related label revisions include:

• Addition of the "never share pens or cartridges" warning following reports of blood-borne pathogen transmission incidents with prefilled insulin devices (added approximately 2012).
• Reformulation of the Medication Guide in plain language per FDA's 2011 guidance on patient labeling.
• Addition of the hypokalemia warning section, which did not appear in the original 2000 label.
• Updated Drug Interactions table reflecting post-approval pharmacokinetic studies with newer antidiabetic agents, including GLP-1 receptor agonists and SGLT-2 inhibitors 2.

A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism examined 25 years of basal insulin pharmacovigilance data and concluded: "The overall safety profile of insulin glargine 100 units/mL as observed in long-term real-world use is consistent with the profile established in pre-approval trials, with hypoglycemia remaining the predominant clinically significant adverse event" 11.

Biosimilars: Regulatory Pathway and Approved Products

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) established the 351(k) pathway for insulin biosimilar approval in the United States. Insulin products transitioned from NDA to BLA oversight on March 23, 2020, meaning all insulin glargine products are now regulated as biologics 12.

Basaglar (Eli Lilly / Boehringer Ingelheim)

Basaglar (insulin glargine-yfgn) received FDA approval in December 2015 as a follow-on biologic to Lantus under BLA 205692. Because the BPCIA framework was not yet fully operational for insulins at that time, Basaglar was approved via an abbreviated NDA pathway referencing Lantus clinical data, rather than as a formal biosimilar. In practice, the clinical use and dosing mirror Lantus 12.

Semglee (Viatris / Biocon): First Interchangeable Insulin Biosimilar

Semglee (insulin glargine-yfgn) achieved a landmark designation on July 28, 2021, when FDA approved it as both biosimilar to and interchangeable with Lantus, making it the first interchangeable insulin biosimilar approved in the United States 12. Interchangeability means that pharmacists may substitute Semglee for Lantus without requiring a new physician prescription, subject to state pharmacy laws. The interchangeability determination rested on three switching studies demonstrating no clinically meaningful difference in immunogenicity or efficacy between alternating Semglee and Lantus versus continuous Lantus use 13.

Rezvoglar (Eli Lilly)

Rezvoglar (insulin glargine-aglr) received FDA approval on December 22, 2022, as a biosimilar to and interchangeable with Lantus 12. Its approval package included comparative analytical, pharmacokinetic, and clinical immunogenicity data per the FDA biosimilar guidance framework.

Regulatory Comparison: Lantus vs. Toujeo (U-300 Glargine)

Toujeo (insulin glargine 300 units/mL) is a distinct Sanofi product that uses the same active molecule as Lantus but at triple the concentration. The FDA approved Toujeo on February 25, 2015, under NDA 206538. The two products are not interchangeable: the U-300 formulation produces a more prolonged, flatter absorption profile compared to U-100 glargine, and direct dose conversion is not 1:1 in all patients 14.

The FDA label for Toujeo carries a separate set of clinical pharmacology data and a distinct pharmacokinetic section documenting the longer duration of action (beyond 36 hours in some patients). The EDITION clinical trial program (EDITION 1 through EDITION 4 and EDITION JP) supported this approval, enrolling more than 3,500 patients across type 1 and type 2 diabetes populations 14.

Clinical Pharmacology Reflected in the Label

Mechanism and Pharmacokinetics

Insulin glargine's acidic formulation (pH 4) renders it fully soluble in the vial. After subcutaneous injection into a physiologic pH environment, it forms microprecipitates that dissolve slowly over approximately 24 hours, producing a relatively flat serum insulin profile without a pronounced peak. The label's Clinical Pharmacology section documents that maximum concentration (Cmax) after subcutaneous injection is reached between 8 and 16 hours in most subjects, with an effective duration of action up to 24 hours 2.

Metabolism and Elimination

Insulin glargine is partially metabolized in the subcutaneous tissue to two active metabolites, M1 and M2, which have insulin-receptor binding activity comparable to regular human insulin. The label notes that renal impairment may reduce insulin requirements, consistent with the general class pharmacology of insulins 2. Hepatic impairment similarly may reduce clearance, warranting closer glucose monitoring and potential dose reduction.

Immunogenicity

All insulins, including glargine, may induce anti-insulin antibodies. In comparative studies cited in the label, the frequency of antibody formation with glargine was similar to that observed with NPH insulin. The presence of antibodies did not correlate with reduced efficacy or increased adverse events in controlled trials 2. The American Diabetes Association Standards of Care note that clinically significant antibody-mediated insulin resistance is rare with modern recombinant insulins 15.

Prescribing Guidance from Major Guidelines

The American Diabetes Association (ADA) 2023 Standards of Care recommend basal insulin as the preferred initial injectable therapy for type 2 diabetes when oral agents fail to achieve glycemic targets, with insulin glargine specifically identified as a well-characterized agent with a favorable nocturnal hypoglycemia profile compared to NPH 15. The ADA guideline states: "Basal insulin analogs (glargine U-100, glargine U-300, detemir, degludec) are associated with less nocturnal hypoglycemia than NPH insulin" 15.

The American Association of Clinical Endocrinology (AACE) 2022 Comprehensive Diabetes Management Algorithm similarly positions glargine-class insulins as preferred basal agents when cost and access barriers are addressed 16. The AACE algorithm notes that the regulatory availability of interchangeable biosimilars such as Semglee provides a cost-reduction pathway for patients requiring long-term basal insulin therapy 16.

A 2012 Cochrane systematic review of long-acting insulin analogs for type 2 diabetes (Cochrane Database Syst Rev, CD005613) found that insulin glargine reduced nocturnal hypoglycemia events by approximately 37% compared to NPH insulin, while producing equivalent HbA1c reductions. The review covered 22 randomized controlled trials with a combined 6,546 patients 17.

Risk Management Without a REMS

Unlike some high-risk biologics, Lantus does not carry a Risk Evaluation and Mitigation Strategy (REMS). The FDA determined that the existing labeling, Medication Guide, and standard pharmacovigilance obligations were sufficient to manage Lantus's known risk profile. This assessment is reviewed periodically as part of FDA's benefit-risk framework for approved products 3.

The Medication Guide required for patient distribution summarizes the risk of severe hypoglycemia in plain language, instructs patients on signs and symptoms, and provides guidance on glucagon emergency kit use. An updated Medication Guide was issued with the 2015 label supplement 2.